PitchBook-2024年四季度医疗技术公共报表和估值指南（英）_5页_552kb

Medtech Public Company Performance Summary: Q4 2024

Stock Returns

The stock returns for medical devices and supplies companies in Q4 2024 show mixed performance, with means of approximately -1.3% for 1-year returns and -0.8% for 5-year returns. Medtronic and Intuitive Surgical demonstrated strong YTD performance (e.g., 57.7% for Medtronic), while others like Baxter experienced losses (-66.0%). Key statistics include mean returns of -1.3% for 1-year and -0.8% for 5-years, with medians slightly less negative at -1.5% and -0.9%. For life sciences and diagnostics, returns vary, with mean 1-year at -2.3% and mean 5-year at -13.7%, and index performance reflects overall market trends, such as S&P 500 at -2.6% for 1-week change.

Valuations

Public medtech companies exhibit varying valuation multiples. Average EV/LTM revenue is around 5.5x-6.7x across sectors, with healthcare companies typically higher than industrial counterparts. EV/LTM EBITDA multiples range from 17x to over 100x, depending on company size and profitability. Industries show differences: medical devices favor higher multiples (up to 19.1x for some), while diagnostics have narrower ranges.

Revenue

Revenue data reveals substantial growth in many companies. Medical devices and supplies saw mean annual growth of 3.5% over the last three years, with Intuitive Surgical recording 155.7% in 2023. Revenue values range from low billions for firms like Insulet ($) to hundreds of billions for Johnson & Johnson ($363.6B). Multiples show consistency in EV/Revenue around 2.4-14.8x, indicating stable valuations despite growth variations.

EBITDA

EBITDA margins and growth highlight operational performance. The sector shows high profitability with means around 30%-50%, and EV/EBITDA multiples range from low 7x for some smaller firms to extremely high 133x for niche companies like Exact Sciences. Growth in EBITDA varies, with some firms like Abbott maintaining steady margins while others face declines, reflecting market dynamics and cost management.

Overall Market Comparison

Medtech companies outperformed broader indices in certain periods, such as 90-day returns with positive gains for most firms, unlike the Nasdaq's 0.5% change. The data underscores resilience in healthcare, with higher valuation multiples and revenue growth offsetting some market volatility.